tirzepatide updates today Big update in pediatric diabetes care 🩺 Mounjaro® (tirzepatide) is now FDA-approved for children ≥10 years old with Type 2 diabetes as an adjunct to diet and exercise. What this means ⬇️ Tirzepatide Compounding Update: FDA Reversal
Description
Contact your healthcare provider immediately if side effects severely impact your quality of life
Tirzepatide carries a boxed warning for thyroid C-cell tumors, including medullary thyroid carcinoma (MTC)
Compounded tirzepatide prescriptions are limited to residents in the following states: AZ, CA, CO, CT, DE, FL, GA, HI, IA, ID, IL, KS, MA, MD, ME, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, TN, TX, UT, VA, VT, WA, WI, WV, Washington D.C., WY
The typical formulation includes 17mg/mL tirzepatide with 2mg/mL niacinamide in 4mL vials, though concentrations vary
Too much of LL-37 has also been associated with inflammatory conditions
